Golgi Neurosciences Partners with CDD Vault to Drive Innovation in Neurodegenerative Disease Treatment

August 29, 2023 04:00 PM AEST | By EIN Presswire
 Golgi Neurosciences Partners with CDD Vault to Drive Innovation in Neurodegenerative Disease Treatment
Image source: EIN Presswire
MILANO, ITALY, August 29, 2023/EINPresswire.com/ -- Golgi Neurosciences S.r.l., a new Italian incubator dedicated to the discovery and development of small molecule-based treatments for neurodegenerative diseases, announced today that it has adopted Collaborative Drug Discovery’s CDD Vault as its platform of choice for managing drug discovery data. This integration will streamline the Company's processes and collaborations, allowing for more efficient research and development.

CDD Vault, a secure, integrated, and intuitive platform with comprehensive features like registration, assay management, electronic laboratory notebooks, and data visualization, will be supporting Golgi Neurosciences' search for innovative treatments for neurodegenerative diseases, including but not limited to Alzheimer's, Parkinson's, Amyotrophic Lateral Sclerosis, Multiple Sclerosis, and Retinopathies.

"As a company fully committed to innovative treatments for neurological disorders, Golgi Neurosciences understands the importance of robust data management," said Chiara Liberati, Managing Director of Golgi Neurosciences. "Adopting CDD Vault allows us to better harness the power of our data, leading to more precise, reliable, and faster research. In addition, the platform permits us to collaborate with our partners in real time facilitating communication and teamwork."

Recently born from Axxam's Discovery Research Unit, Golgi Neurosciences has established a valuable pipeline, together with a rich portfolio of participated companies, tackling a range of serious neurological diseases. By adopting CDD Vault, it aims to augment its research data capabilities, enabling more efficient access to, and organization of, critical research data.

“It is a real privilege to support Golgi Neurosciences in the search for novel treatments of neurodegenerative diseases, a challenging research area with many unmet medical needs”, said Dr Barry Bunin, Founder and CEO of CDD. “Golgi Neurosciences’ research has the potential to be a game changer in the field and it represents a beacon of hope for the many patients awaiting new treatments. We are looking forward to supporting Golgi Neurosciences on the quest.”

About Golgi Neurosciences
Golgi Neurosciences is a biotech incubator based in Milan, Italy, dedicated to the discovery and development of small molecule-based treatments for neurodegenerative diseases with high unmet need. The incubator boasts a diverse portfolio of clinical and preclinical stage companies, all focused on programs targeting various neurodegenerative diseases, including Alzheimer’s, Parkinson’s, Amyotrophic Lateral Sclerosis, Multiple Sclerosis and Retinopathies. In addition, Golgi Neurosciences is progressing a robust pipeline of proprietary projects on innovative therapeutics targets, for which it is open to partnership.
For more information, please visit: www.golgineurosciences.com

About Collaborative Drug Discovery
CDD's (www.collaborativedrug.com) flagship product, "CDD Vault®", is used to manage chemical registration, structure-activity relationships (SAR), and securely scale collaborations. CDD Vault® is a hosted database solution for secure management and sharing of biological and chemical data. It lets you intuitively organize chemical structures and biological study data, and collaborate with internal or external partners through an easy to use web interface. Available modules within CDD Vault include Activity & Registration, Visualization, Inventory, and ELN.

Mariana Vaschetto
Collaborative Drug Discovery
email us here


Disclaimer

The content, including but not limited to any articles, news, quotes, information, data, text, reports, ratings, opinions, images, photos, graphics, graphs, charts, animations and video (Content) is a service of Kalkine Media Pty Ltd (Kalkine Media, we or us), ACN 629 651 672 and is available for personal and non-commercial use only. The principal purpose of the Content is to educate and inform. The Content does not contain or imply any recommendation or opinion intended to influence your financial decisions and must not be relied upon by you as such. Some of the Content on this website may be sponsored/non-sponsored, as applicable, but is NOT a solicitation or recommendation to buy, sell or hold the stocks of the company(s) or engage in any investment activity under discussion. Kalkine Media is neither licensed nor qualified to provide investment advice through this platform. Users should make their own enquiries about any investments and Kalkine Media strongly suggests the users to seek advice from a financial adviser, stockbroker or other professional (including taxation and legal advice), as necessary. Kalkine Media hereby disclaims any and all the liabilities to any user for any direct, indirect, implied, punitive, special, incidental or other consequential damages arising from any use of the Content on this website, which is provided without warranties. The views expressed in the Content by the guests, if any, are their own and do not necessarily represent the views or opinions of Kalkine Media. Some of the images/music that may be used on this website are copyright to their respective owner(s). Kalkine Media does not claim ownership of any of the pictures displayed/music used on this website unless stated otherwise. The images/music that may be used on this website are taken from various sources on the internet, including paid subscriptions or are believed to be in public domain. We have used reasonable efforts to accredit the source wherever it was indicated as or found to be necessary.


AU_advertise

Advertise your brand on Kalkine Media

Sponsored Articles


Investing Ideas

Previous Next
We use cookies to ensure that we give you the best experience on our website. If you continue to use this site we will assume that you are happy with it.